The Trump administration this month initiated Section 232 investigations into imports of semiconductors and pharmaceuticals, ...

Experts say the tariffs are unlikely to bring back production of generic medicines, given their slim profit margins ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Amgen (AMGN) stock in focus as Sandoz files antitrust lawsuit alleging that the company blocked copycats from targeting its ...

Steffen Lang, president, operations, executive committee member, Novartis, discusses what to expect from Novartis over the next decade in terms of technological innovations.

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

WHO is nearing a treaty for future pandemics, Novartis invests $23 billion in the US amidst drug tariff threats, and measles ...

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...